drugset / Trial / NCT06300528
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this clinical trial is to learn if the study drug pemigatinib is effective in treating patients with relapsed or refractory B-cell non-Hodgkin lymphomas.
Timeline
- Start
- 2025-10-03
- Primary completion
- 2026-03-16
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemigatinib | Small molecule | — | Oral |